Prevalence of <scp>SGLT2</scp> inhibitor and <scp>GLP1</scp> receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset
We observed low rates of SGLT2 inhibitor and GLP1-RA prescriptions in patients with T2DM irrespective of CKD status. Strategies are needed to improve prescription rates, with a particular focus on patients with high kidney and cardiovascular risk.
Authors
- Takaya Sasaki (ORCID: https://orcid.org/0000-0001-9525-2638)
- David Peiris (ORCID: https://orcid.org/0000-0002-6898-3870)
- James Wick (ORCID: https://orcid.org/0000-0002-1210-5294)
- Brendon Lange Neuen (ORCID: https://orcid.org/0000-0001-9276-8380)
- Anthony Rodgers (ORCID: https://orcid.org/0000-0003-1282-1896)
- Sallie‐Anne Pearson (ORCID: https://orcid.org/0000-0001-7137-6855)
- Hannah Wallace (ORCID: https://orcid.org/0000-0002-2728-4299)
- Jeffrey T. Ha (ORCID: https://orcid.org/0000-0002-8558-1697)
- Mark Woodward (ORCID: https://orcid.org/0000-0001-9800-5296)
- Jialing Lin (ORCID: https://orcid.org/0000-0002-0643-9191)
- Paul E. Ronksley (ORCID: https://orcid.org/0000-0002-3958-7561)
- John Chalmers (ORCID: https://orcid.org/0000-0002-9931-0580)
- Daniel Bekele Ketema (ORCID: https://orcid.org/0000-0002-7464-7814)
- Michael O. Falster (ORCID: https://orcid.org/0000-0001-6444-7272)
- Craig Nelson (ORCID: https://orcid.org/0000-0003-3548-4167)
- Luke Buizen
- Juliana de Oliveira Costa (ORCID: https://orcid.org/0000-0002-8355-023X)
- Sunil V. Badve (ORCID: https://orcid.org/0000-0003-2269-312X)
- Martin Gallagher (ORCID: https://orcid.org/0000-0001-9187-6187)
- Sradha S. Kotwal (ORCID: https://orcid.org/0000-0002-3294-4087)
- Min Jun (ORCID: https://orcid.org/0000-0003-1460-7535)
- Meg Jardine (ORCID: https://orcid.org/0000-0002-0160-2375)
Institutions
- The University of Sydney (AU)
- University of Calgary (CA)
- The George Institute for Global Health (GB)
- UNSW Sydney (AU)
- The George Institute for Global Health (AU)
- Western Health (AU)
- Melbourne Health (AU)
- National Health and Medical Research Council (AU)
- Imperial College London (GB)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-07-16
- DOI
- https://doi.org/10.1111/dom.16608
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.88
Funders
- Eli Lilly and Company
- Australian Commission on Safety and Quality in Health Care
- David and Elaine Potter Foundation
- Australian Government
- Ian Potter Foundation
- University of New South Wales
- University of Melbourne
- George Institute for Global Health
- Eli Lilly Australia
- Faculty of Medicine and Health, University of Sydney